These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16914220)

  • 1. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.
    Vink SR; Schellens JH; Beijnen JH; Sindermann H; Engel J; Dubbelman R; Moppi G; Hillebrand MJ; Bartelink H; Verheij M
    Radiother Oncol; 2006 Aug; 80(2):207-13. PubMed ID: 16914220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours.
    Unger C; Berdel W; Hanauske AR; Sindermann H; Engel J; Mross K
    Eur J Cancer; 2010 Mar; 46(5):920-5. PubMed ID: 20079628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.
    Bailey HH; Mahoney MR; Ettinger DS; Maples WJ; Fracasso PM; Traynor AM; Erlichman C; Okuno SH
    Cancer; 2006 Nov; 107(10):2462-7. PubMed ID: 17058289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours.
    de Jonge MJ; Dumez H; Verweij J; Yarkoni S; Snyder D; Lacombe D; Marréaud S; Yamaguchi T; Punt CJ; van Oosterom A;
    Eur J Cancer; 2006 Aug; 42(12):1768-74. PubMed ID: 16815702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas.
    Tedesco KL; Berlin J; Rothenberg M; Choy H; Wyman K; Scott Pearson A; Daniel Beauchamp R; Merchant N; Lockhart AC; Shyr Y; Caillouette C; Chakravarthy B
    Radiother Oncol; 2005 Jul; 76(1):54-8. PubMed ID: 15921772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC).
    Vestermark LW; Jacobsen A; Qvortrup C; Hansen F; Bisgaard C; Baatrup G; Rasmussen P; Pfeiffer P
    Acta Oncol; 2008; 47(3):428-33. PubMed ID: 18348002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 2 study of perifosine in advanced or metastatic breast cancer.
    Leighl NB; Dent S; Clemons M; Vandenberg TA; Tozer R; Warr DG; Crump RM; Hedley D; Pond GR; Dancey JE; Moore MJ
    Breast Cancer Res Treat; 2008 Mar; 108(1):87-92. PubMed ID: 17458693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
    Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
    J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
    Lockhart AC; Bukowski R; Rothenberg ML; Wang KK; Cooper W; Grover J; Appleman L; Mayer PR; Shapiro M; Zhu AX
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
    Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.
    Crul M; Rosing H; de Klerk GJ; Dubbelman R; Traiser M; Reichert S; Knebel NG; Schellens JH; Beijnen JH; ten Bokkel Huinink WW
    Eur J Cancer; 2002 Aug; 38(12):1615-21. PubMed ID: 12142051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine.
    Shome D; Trent J; Espandar L; Hatef E; Araujo DM; Song CD; Kim SK; Esmaeli B
    Ophthalmology; 2008 Mar; 115(3):483-7. PubMed ID: 18201764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts.
    Vink SR; Lagerwerf S; Mesman E; Schellens JH; Begg AC; van Blitterswijk WJ; Verheij M
    Clin Cancer Res; 2006 Mar; 12(5):1615-22. PubMed ID: 16533789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
    Mita AC; Denis LJ; Rowinsky EK; Debono JS; Goetz AD; Ochoa L; Forouzesh B; Beeram M; Patnaik A; Molpus K; Semiond D; Besenval M; Tolcher AW
    Clin Cancer Res; 2009 Jan; 15(2):723-30. PubMed ID: 19147780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies.
    Dritschilo A; Huang CH; Rudin CM; Marshall J; Collins B; Dul JL; Zhang C; Kumar D; Gokhale PC; Ahmad A; Ahmad I; Sherman JW; Kasid UN
    Clin Cancer Res; 2006 Feb; 12(4):1251-9. PubMed ID: 16489081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
    Gogna NK; Matthews JH; Turner SL; Mameghan H; Duchesne GM; Spry N; Berry MP; Keller J; Tripcony L;
    Radiother Oncol; 2006 Oct; 81(1):9-17. PubMed ID: 17011058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors.
    Planting A; van der Gaast A; Schöffski P; Bartkowski M; Verheij C; Noe D; Ferrante K; Verweij J
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):136-42. PubMed ID: 15592721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.